Patents by Inventor Robert Goodenow

Robert Goodenow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION 94919.0739.717301US
    Publication number: 20240058304
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 22, 2024
    Inventors: Gary ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Jay MASON, Waldemar RADZISZEWSKI, Suzanne ROMANO
  • Sulcardine administration for treatment of acute atrial fibrillation
    Patent number: 11813245
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 14, 2023
    Assignee: HUYABIO International, LLC
    Inventors: Gary Elliott, Mireille Gillings, Robert Goodenow, Jay Mason, Waldemar Radziszewski, Suzanne Romano
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20230022573
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: April 8, 2022
    Publication date: January 26, 2023
    Applicant: Syndax Pharmaceuticals, Inc.
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS
    Publication number: 20220370456
    Abstract: Provided herein are combinations that include a SHP2 inhibitor and an EGFR TKI and methods of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • SHP2 INHIBITOR MONOTHERAPY AND USES THEREOF
    Publication number: 20220370458
    Abstract: Provided herein are SHP2 inhibitors for use in the reduction of solid tumors in a method of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20220370457
    Abstract: Provided herein are combinations that include a SHP2 inhibitor and a PD-1 inhibitor and methods of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • SULCARDINE SALTS
    Publication number: 20220356319
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: July 11, 2022
    Publication date: November 10, 2022
    Inventors: Suzanne J. ROMANO, Hayley Ann REECE, Joseph Edward Gordon BENSON, Sarah COLLINS, Gary T. ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Curtis TYREE
  • Sulcardine salts
    Patent number: 11426382
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 30, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
    Patent number: 11324822
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 10, 2022
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Robert Goodenow, Peter Ordentlich
  • METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS
    Publication number: 20220110924
    Abstract: Provided herein is a therapy comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.
    Type: Application
    Filed: August 24, 2021
    Publication date: April 14, 2022
    Inventors: Reid P. BISSONNETTE, Rosemary M. CESARIO, Robert GOODENOW, Farbod SHOJAEI, Mireille GILLINGS
  • SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION
    Publication number: 20210386708
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Inventors: Gary ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Jay MASON, Waldemar RADZISZEWSKI, Suzanne ROMANO
  • Sulcardine salts
    Patent number: 11020374
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 1, 2021
    Assignee: HUYA Bioscience International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • SULCARDINE SALTS
    Publication number: 20210038568
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Suzanne J. ROMANO, Hayley Ann REECE, Joseph Edward Gordon BENSON, Sarah COLLINS, Gary T. ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Curtis TYREE
  • SULCARDINE SALTS
    Publication number: 20200316024
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: January 28, 2020
    Publication date: October 8, 2020
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20190343844
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: January 15, 2019
    Publication date: November 14, 2019
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • Methods for the treatment of breast cancer
    Patent number: 10226472
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 12, 2019
    Assignee: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS
    Publication number: 20190046513
    Abstract: Provided herein are combinations that include a histone deacetylase inhibitor and tubulin inhibitor such as eribulin or a pharmaceutically acceptable salt thereof that are useful for treating cancer, including reducing cancer metastasis.
    Type: Application
    Filed: August 14, 2017
    Publication date: February 14, 2019
    Inventors: Reid P. Bissonnette, Alain Rolland, Robert Goodenow, Mireille Gillings
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20180353602
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of metastatic triple negative breast cancer with a combination of entinostat and an anti-PD-L1 antibody, such as MPDL3280A.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 13, 2018
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20180078639
    Abstract: Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 22, 2018
    Inventors: Robert GOODENOW, Peter ORDENTLICH
  • METHODS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20140378420
    Abstract: Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 25, 2014
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Robert Goodenow, Peter Ordentlich